Skip to main content
OpenTrials
Completed

NCT Number: NCT02241772

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Elevated Lp(a)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Herlev Hospital

Herlev, DK-2730, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels

Exclusion criteria

  • Clinically significant medical history
  • Abnormal laboratory results (other than lipid levels) or vital signs
  • Receiving any other drug therapy

Treatment and study plan

TA-8995

Drug

Placebo

Drug

Primary outcomes

  1. To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Xention Ltd

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Sep 16, 2014
Registry last updated
Feb 16, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.